Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 691

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Open access
Kennedy, Nicholas A, Heap, Graham A, Green, Harry D, Hamilton, Benjamin, Bewshea, Claire, Walker, Gareth J, Thomas, Amanda, Nice, Rachel, Perry, Mandy H, Bouri, Sonia, Chanchlani, Neil, Heerasing, Neel M, Hendy, Peter, Lin, Simeng, Gaya, Daniel R, Cummings, J R Fraser, Selinger, Christian P, Lees, Charlie W, Hart, Ailsa L, Parkes, Miles, Sebastian, Shaji, Mansfield, John C, Irving, Peter M, Lindsay, James, Russell, Richard K, McDonald, Timothy J, McGovern, Dermot, Goodhand, James R, Ahmad, Tariq, Patel, Vinod, Mazhar, Zia, Saich, Rebecca, Colleypriest, Ben, Tham, Tony C, Iqbal, Tariq H, Kaushik, Vishal, Murugesan, Senthil, Singh, Salil, Weaver, Sean, Preston, Cathryn, Butt, Assad, Smith, Melissa, Basude, Dharamveer, Beale, Amanda, Langlands, Sarah, Direkze, Natalie, Parkes, Miles, Torrente, Franco, De La Revella Negro, Juan, MacDonald, Chris Ewen, Evans, Stephen M, Gunasekera, Anton V J, Thakur, Alka, Elphick, David, Shenoy, Achuth, Nwokolo, Chuka U, Dhar, Anjan, Cole, Andrew T, Agrawal, Anurag, Bridger, Stephen, Doherty, Julie, Cooper, Sheldon C, de Silva, Shanika, Mowat, Craig, Mayhead, Phillip, Lees, Charlie, Jones, Gareth, Ahmad, Tariq, Hart, James W, Gaya, Daniel R, Russell, Richard K, Gervais, Lisa, Dunckley, Paul, Mahmood, Tariq, Banim, Paul J R, Sonwalkar, Sunil, Ghosh, Deb, Phillips, Rosemary H, Azaz, Amer, Sebastian, Shaji, Shenderey, Richard, Armstrong, Lawrence, Bell, Claire, Hariraj, Radhakrishnan, Matthews, Helen, Jafferbhoy, Hasnain, Selinger, Christian P, Zamvar, Veena, De Caestecker, John S, Willmott, Anne, Miller, Richard, Babu, Palani Sathish, Tzivinikos, Christos, Bloom, Stuart L, Chung-Faye, Guy, Croft, Nicholas M, Fell, John ME, Harbord, Marcus, Hart, Ailsa, Hope, Ben, Irving, Peter M, Lindsay, James O, Mawdsley, Joel E, McNair, Alistair, Monahan, Kevin J, Murray, Charles D, Orchard, Timothy, Paul, Thankam, Pollok, Richard, Shah, Neil, Bouri, Sonia, Johnson, Matt W, Modi, Anita, Kabiru, Kasamu Dawa, Baburajan, B K, Bhaduri, Bim, Fagbemi, Andrew Adebayo, Levison, Scott, Limdi, Jimmy K, Watts, Gill, Foley, Stephen, Ramadas, Arvind, MacFaul, George, Mansfield, John, Grellier, Leonie, Morris, Mary-Anne, Tremelling, Mark, Hawkey, Chris, Kirkham, Sian, Charlton, Charles PJ, Rodrigues, Astor, Simmons, Alison, Lewis, Stephen J, Snook, Jonathon, Tighe, Mark, Goggin, Patrick M, De Silva, Aminda N, Lal, Simon, Smith, Mark S, Panter, Simon, Cummings, J R Fraser, Dharmisari, Suranga, Carter, Martyn, Watts, David, Mahmood, Zahid, McLain, Bruce, Sen, Sandip, Pigott, Anna J, Hobday, David, Wesley, Emma, Johnston, Richard, Edwards, Cathryn, Beckly, John, Vani, Deven, Ramakrishnan, Subramaniam, Chaudhary, Rakesh, Trudgill, Nigel J, Cooney, Rachel, Bell, Andy, Prasad, Neeraj, Gordon, John N, Brookes, Matthew J, Li, Andy, Gore, Stephen·2019·The Lancet Gastroenterology & Hepatology

Abstract

BACKGROUND Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors that predict primary non-response at week 14 after starting treatment, non-remission at week 54, and adverse events leading to drug withdrawal. METHODS The personalised anti-TNF therapy in Crohn's disease study (PANTS) is a prospective observational UK-wide study. We enrolled anti-TNF-naive patients (aged ≥6 years) with active luminal Crohn's disease at the time of first exposure to infliximab or adalimumab between March 7, 2013, and July 15, 2016. Patients were evaluated for 12 months or until drug withdrawal. Demographic data, smoking status, age at diagnosis, disease duration, location, and behaviour, previous medical and drug history, and previous Crohn's disease-related surgeries were recorded at baseline. At every visit, disease activity score, weight, therapy, and adverse events were recorded; drug and total anti-drug antibody concentrations were also measured. Treatment failure endpoints were primary non-response at week 14, non-remission at week 54, and adverse events leading to drug withdrawal. We used regression analyses to identify which factors were associated with treatment failure. FINDINGS We enrolled 955 patients treated with infliximab (753 with originator; 202 with biosimilar) and 655 treated with adalimumab. Primary non-response occurred in 295 (23·8%, 95% CI 21·4-26·2) of 1241 patients who were assessable at week 14. Non-remission at week 54 occurred in 764 (63·1%, 60·3-65·8) of 1211 patients who were assessable, and adverse events curtailed treatment in 126 (7·8%, 6·6-9·2) of 1610 patients. In multivariable analysis, the only factor independently associated with primary non-response was low drug concentration at week 14 (infliximab: odds ratio 0·35 [95% CI 0·20-0·62], p=0·00038; adalimumab: 0·13 [0·06-0·28], p<0·0001); the optimal week 14 drug concentrations associated with remission at both week 14 and week 54 were 7 mg/L for infliximab and 12 mg/L for adalimumab. Continuing standard dosing regimens after primary non-response was rarely helpful; only 14 (12·4% [95% CI 6·9-19·9]) of 113 patients entered remission by week 54. Similarly, week 14 drug concentration was also independently associated with non-remission at week 54 (0·29 [0·16-0·52] for infliximab; 0·03 [0·01-0·12] for adalimumab; p<0·0001 for both). The proportion of patients who developed anti-drug antibodies (immunogenicity) was 62·8% (95% CI 59·0-66·3) for infliximab and 28·5% (24·0-32·7) for adalimumab. For both drugs, suboptimal week 14 drug concentrations predicted immunogenicity, and the development of anti-drug antibodies predicted subsequent low drug concentrations. Combination immunomodulator (thiopurine or methotrexate) therapy mitigated the risk of developing anti-drug antibodies (hazard ratio 0·39 [95% CI 0·32-0·46] for infliximab; 0·44 [0·31-0·64] for adalimumab; p<0·0001 for both). For infliximab, multivariable analysis of immunododulator use, and week 14 drug and anti-drug antibody concentrations showed an independent effect of immunomodulator use on week 54 non-remission (odds ratio 0·56 [95% CI 0·38-0·83], p=0·004). INTERPRETATION Anti-TNF treatment failure is common and is predicted by low drug concentrations, mediated in part by immunogenicity. Clinical trials are required to investigate whether personalised induction regimens and treatment-to-target dose intensification improve outcomes. FUNDING Guts UK, Crohn's and Colitis UK, Cure Crohn's Colitis, AbbVie, Merck Sharp and Dohme, Napp Pharmaceuticals, Pfizer, and Celltrion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(19)30012-3

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 691

Metadata

Authors
Kennedy, N. A., Heap, G. A., Green, H. D., Hamilton, B., Bewshea, C., Walker, G. J., Thomas, A., Nice, R., Perry, M. H., Bouri, S., Chanchlani, N., Heerasing, N. M., Hendy, P., Lin, S., Gaya, D. R., Cummings, J. R. F., Selinger, C. P., Lees, C. W., Hart, A. L., Parkes, M., Sebastian, S., Mansfield, J. C., Irving, P. M., Lindsay, J., Russell, R. K., McDonald, T. J., McGovern, D., Goodhand, J. R., Ahmad, T., Patel, V., Mazhar, Z., Saich, R., Colleypriest, B., Tham, T. C., Iqbal, T. H., Kaushik, V., Murugesan, S., Singh, S., Weaver, S., Preston, C., Butt, A., Smith, M., Basude, D., Beale, A., Langlands, S., Direkze, N., Parkes, M., Torrente, F., De La Revella Negro, J., MacDonald, C. E., Evans, S. M., Gunasekera, A. V. J., Thakur, A., Elphick, D., Shenoy, A., Nwokolo, C. U., Dhar, A., Cole, A. T., Agrawal, A., Bridger, S., Doherty, J., Cooper, S. C., de Silva, S., Mowat, C., Mayhead, P., Lees, C., Jones, G., Ahmad, T., Hart, J. W., Gaya, D. R., Russell, R. K., Gervais, L., Dunckley, P., Mahmood, T., Banim, P. J. R., Sonwalkar, S., Ghosh, D., Phillips, R. H., Azaz, A., Sebastian, S., Shenderey, R., Armstrong, L., Bell, C., Hariraj, R., Matthews, H., Jafferbhoy, H., Selinger, C. P., Zamvar, V., De Caestecker, J. S., Willmott, A., Miller, R., Babu, P. S., Tzivinikos, C., Bloom, S. L., Chung-Faye, G., Croft, N. M., Fell, J. M., Harbord, M., Hart, A., Hope, B., Irving, P. M., Lindsay, J. O., Mawdsley, J. E., McNair, A., Monahan, K. J., Murray, C. D., Orchard, T., Paul, T., Pollok, R., Shah, N., Bouri, S., Johnson, M. W., Modi, A., Kabiru, K. D., Baburajan, B. K., Bhaduri, B., Fagbemi, A. A., Levison, S., Limdi, J. K., Watts, G., Foley, S., Ramadas, A., MacFaul, G., Mansfield, J., Grellier, L., Morris, M.-A., Tremelling, M., Hawkey, C., Kirkham, S., Charlton, C. P., Rodrigues, A., Simmons, A., Lewis, S. J., Snook, J., Tighe, M., Goggin, P. M., De Silva, A. N., Lal, S., Smith, M. S., Panter, S., Cummings, J. R. F., Dharmisari, S., Carter, M., Watts, D., Mahmood, Z., McLain, B., Sen, S., Pigott, A. J., Hobday, D., Wesley, E., Johnston, R., Edwards, C., Beckly, J., Vani, D., Ramakrishnan, S., Chaudhary, R., Trudgill, N. J., Cooney, R., Bell, A., Prasad, N., Gordon, J. N., Brookes, M. J., Li, A., & Gore, S.
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2019-05
Volume
4
Issue
5
Pages
341-353
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W2916794721
Cited by
691
References
31
FWCI
44.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. https://app.cochat.ai/papers/10.1016/s2468-1253(19)30012-3
The paper
Kennedy, N. A., Heap, G. A., Green, H. D., Hamilton, B., Bewshea, C., Walker, G. J., Thomas, A., Nice, R., Perry, M. H., Bouri, S., Chanchlani, N., Heerasing, N. M., Hendy, P., Lin, S., Gaya, D. R., Cummings, J. R. F., Selinger, C. P., Lees, C. W., Hart, A. L., . . . Gore, S. (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(19)30012-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.